Latest news
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform - Yahoo FinanceYahoo Finance · Mon, 03 Aug 2026 13:02:00 GMTVaximm's Two Glioblastoma Studies Had No Dose-Limiting Toxicities - Stock TitanStock Titan · Mon, 03 Aug 2026 13:02:00 GMT